冠心病高脂血症患者应用阿托伐他汀长期调脂治疗的临床观察

目的研究冠心病、高脂血症患者长期应用阿托伐他汀调脂治疗的临床疗效、不良反应。方法110例冠心病、高脂血症患者在膳食控制和适当加强锻炼的基础上服用阿托伐他汀10～20mg,每晚1次;治疗6～12周后将达到治疗目标的患者改为服用阿托伐他汀10mg,隔日晚服1次,维持应用。每12周测总胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、肝、肾功能、肌酸激酶（CK）。结果治疗6～12周后TC、LDL-C达调脂治疗目标值为89例（80.9%）,TC、TG、LDL-C下降,HDL-C升高,与治疗前比较差异有统计学意义（P〈0.01）。维持用药各时期各项指标比较差异无统计学意义（P〉0.05）;用药期间无明显肝肾功能损害及不良反应。结论阿托伐他汀调脂作用肯定,在10～20mg每晚1次的剂量下不良反应少,用药安全。在调脂达到目标值后,改为阿托伐他汀10mg,隔日晚服1次,长期维持,临床达标率亦满意。

Clinical observation on long-term lipid-regulating treatment with atorvastatin on coronary and hyperlipoproteinemia patients (CHP)

Objective To study clinical efficacy and adverse reactions of long-term lipid-regulating treatment with atorvastatin on CHP.Methods 110 cases of CHP were administered atorvastain 10mg to 20mg each evening,along with dietary control and proper exercise.The cases whose treatment target values had been reached would alter doses to 10mg each other evening.TC、TG、HDL-C、CK and functions of liver and kidney were measured each 12 weeks.Results After treatment for 6 to 12 weeks,89 cases（80.9%）reached treatment values of TC,LDL-C among which the TC,TG and LDL-C decreased,but HDL-C increased.The above-mentioned indices were significantly different from those before treatment（P〈0.01）.Continued the altered administration of atorvastatin,all indices at each stage had no significant difference（P〉0.05）.There were no obvious injuries to the functions of liver and kidney,and adverse reactions.Conclusion Atorvastatin＇s action in lipid-regulating was definite and with dose of 10mg to 20mg every other evening,the administration was safe.When lipid-lowering reached the target values,the dose was altered to 10mg every other evening and maintained long and clinical target rate was satisfied.